Understanding Stem Cell Therapy in Parkinson’s Disease Treatment

On April 29, 2018, the Washington Post published an article

examining commercial stem cell clinics in the United States that market non-FDA approved treatments directly to the public for a variety of health issues, including arthritis, macular degeneration and of particular note to us, Parkinson’s disease (PD).

Pictured: Dopamine neurons derived from iPSCs from the lab of Xiaobo Mao, Phd

Read More


New York, NY, August 28, 2017 – The American Parkinson Disease Association is pleased to share with the Parkinson’s community the arrival of a new medication in the treatment arsenal to address Parkinson’s symptoms. Approved August 24 by the U.S. Food and Drug Administration is GOCOVRI™ (amantadine) developed by Adamas.  GOCOVRI is an extended release […]

Read More

The Use of Botulinum Toxin (Botox) in Parkinson’s Disease

Botulinum toxin is the most potent biological toxin known to exist. Fortunately, science has harnessed its potential and made it available to treat a number of troublesome disorders. Currently, there are two serotypes of botulinum toxin that are FDA approved for human use, Botox® (Botulinum toxin type A) and Myobloc® (Botulinum toxin type B). Botulinum […]

Read More